NASDAQ:CTSO Cytosorbents (CTSO) Stock Forecast, Price & News $1.73 -0.05 (-2.81%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$1.72▼$1.8150-Day Range$1.73▼$3.8052-Week Range$1.03▼$4.59Volume42,266 shsAverage Volume72,925 shsMarket Capitalization$76.74 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cytosorbents MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside174.6% Upside$4.75 Price TargetShort InterestBearish3.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 2 Articles This WeekInsider TradingAcquiring Shares$9,570 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector650th out of 966 stocksSurgical & Medical Instruments Industry70th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Cytosorbents has a forecasted upside of 174.6% from its current price of $1.73.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.18% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently increased by 19.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 3.2 News and Social Media Coverage News SentimentCytosorbents has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cytosorbents this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,570.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 34.23% of the stock of Cytosorbents is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.55) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cytosorbents (NASDAQ:CTSO) StockCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More CTSO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTSO Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comCytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR RegistrySeptember 19, 2023 | markets.businessinsider.comCytoSorbents Announces Reappointment Of Kathleen Bloch As Full-time CFOOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 19, 2023 | finance.yahoo.comCytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial OfficerSeptember 11, 2023 | finance.yahoo.comCytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ TransplantationSeptember 2, 2023 | seekingalpha.comCytoSorbents announces resignation of CFO Alexander D'AmicoSeptember 1, 2023 | finance.yahoo.comCytoSorbents Announces Resignation of Chief Financial Officer Alexander D’AmicoAugust 31, 2023 | finance.yahoo.comCytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in BrazilOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. August 27, 2023 | finance.yahoo.comCytosorbents (NASDAQ:CTSO) shareholders have endured a 83% loss from investing in the stock five years agoAugust 14, 2023 | finance.yahoo.comCytoSorbents Completes U.S. and Canadian STAR-T Pivotal TrialAugust 3, 2023 | finance.yahoo.comCTSO: CytoSorbents reports 2nd quarter 2023 financial and results which showed strong product revenue growth and an improved cost structure.August 3, 2023 | msn.comHC Wainwright & Co. Reiterates Cytosorbents (CTSO) Buy RecommendationAugust 2, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Cytosorbents (CTSO)August 2, 2023 | msn.comCytosorbents (CTSO) Price Target Increased by 10.53% to 8.57August 1, 2023 | washingtonpost.comCytoSorbents: Q2 Earnings SnapshotAugust 1, 2023 | finance.yahoo.comCytoSorbents Reports Second Quarter 2023 Financial and Operational ResultsJuly 31, 2023 | finance.yahoo.comSeveral Insiders Invested In Cytosorbents Flagging Positive NewsJuly 27, 2023 | finance.yahoo.comCytoSorbents to Report Second Quarter 2023 Operating and Financial ResultsJuly 19, 2023 | markets.businessinsider.comCytosorbents Appoints Alexander D'Amico New CFOJuly 11, 2023 | finance.yahoo.comCytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver DiseaseJuly 9, 2023 | finance.yahoo.comCytosorbents Corporation's (NASDAQ:CTSO) largest shareholders are retail investors with 52% ownership, institutions own 33%July 7, 2023 | finance.yahoo.comCytoSorbents Completes Enrollment of the STAR-T Pivotal TrialJuly 6, 2023 | msn.comCytosorbents (CTSO) Price Target Increased by 8.57% to 7.75June 15, 2023 | finance.yahoo.comCTSO - Cytosorbents CorporationJune 15, 2023 | finance.yahoo.comCytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety ReviewJune 5, 2023 | finance.yahoo.comCytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare ConferenceSee More Headlines Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address CTSO Company Calendar Last Earnings8/01/2023Today10/03/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees198Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.75 High Stock Price Forecast$5.50 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+174.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,810,000.00 Net Margins-72.71% Pretax Margin-75.71% Return on Equity-82.93% Return on Assets-44.94% Debt Debt-to-Equity Ratio0.21 Current Ratio2.28 Quick Ratio2.09 Sales & Book Value Annual Sales$34.69 million Price / Sales2.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book2.14Miscellaneous Outstanding Shares44,360,000Free Float40,769,000Market Cap$76.74 million OptionableOptionable Beta0.84 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Phillip P. Chan M.D. (Age 53)Ph.D., CEO & Director Comp: $541.93kMr. Vincent J. Capponi M.S. (Age 65)MS, Pres & COO Comp: $452.62kMs. Kathleen P. Bloch C.P.A. (Age 68)CPA, M.B.A., MBA, Chief Financial Officer Comp: $395.43kDr. Efthymios N. Deliargyris FACC (Age 54)FESC, FSCAI, M.D., Chief Medical Officer Comp: $463.15kMs. Terri Anne Powers M.B.A.VP of Investor Relations & Corp. CommunicationsDr. Christian Steiner M.D.Exec. VP of Sales & MarketingMr. Christopher Cramer M.B.A.M.S., MBA, MS, Sr. VP of Bus. Devel.Dr. Irina B. Kulinets Ph.D. (Age 68)Sr. VP of Global Regulatory Affairs Jodi HooverExec.Dr. Robert H. Bartlett M.D. (Age 84)Co-Chairman of Cardiac Surgery Advisory Board & Consultant More ExecutivesKey CompetitorsMonogram OrthopaedicsNASDAQ:MGRMBeyond AirNASDAQ:XAIRHealth Sciences Acquisitions Co. 2NASDAQ:HSAQCarmell TherapeuticsNASDAQ:CTCXAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPAView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 7,500 shares on 8/15/2023Ownership: 0.000%Granahan Investment Management LLCBought 49,047 shares on 8/14/2023Ownership: 3.644%Avenir CorpBought 164,179 shares on 8/11/2023Ownership: 6.131%BlackRock Inc.Bought 15,107 shares on 8/11/2023Ownership: 1.713%Regal Investment Advisors LLCBought 5,134 shares on 8/11/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions CTSO Stock - Frequently Asked Questions Should I buy or sell Cytosorbents stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks. What is Cytosorbents' stock price forecast for 2023? 2 equities research analysts have issued 12-month price objectives for Cytosorbents' stock. Their CTSO share price forecasts range from $4.00 to $5.50. On average, they predict the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 174.6% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts. How have CTSO shares performed in 2023? Cytosorbents' stock was trading at $1.55 at the beginning of 2023. Since then, CTSO stock has increased by 11.6% and is now trading at $1.73. View the best growth stocks for 2023 here. Are investors shorting Cytosorbents? Cytosorbents saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,220,000 shares, an increase of 19.6% from the August 31st total of 1,020,000 shares. Based on an average daily volume of 66,000 shares, the days-to-cover ratio is currently 18.5 days. Currently, 3.2% of the company's stock are sold short. View Cytosorbents' Short Interest. When is Cytosorbents' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CTSO earnings forecast. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Tuesday, August, 1st. The medical research company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. The medical research company earned $9.42 million during the quarter, compared to analyst estimates of $11.03 million. Cytosorbents had a negative net margin of 72.71% and a negative trailing twelve-month return on equity of 82.93%. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $1.73. How much money does Cytosorbents make? Cytosorbents (NASDAQ:CTSO) has a market capitalization of $76.74 million and generates $34.69 million in revenue each year. The medical research company earns $-32,810,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How many employees does Cytosorbents have? The company employs 198 workers across the globe. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650. This page (NASDAQ:CTSO) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.